MERCK KGAA DM 5 | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (23)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Article By: ChinaBio® Today
Saturday, November 4, 2023 3:00 PM EDT
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have rights to manufacture and commercialize the drug.
In this article: MKGAF, BLRX, CHRS, IVBXF, SHJBF Also: LLY
Read
Merck KGaA (MKGAF) Q3 Earnings Up Y/Y, 2016 View Intact
Article By: Zacks Investment Research
Tuesday, November 15, 2016 7:45 AM EDT
Merck KGaA's third-quarter 2016 earnings per American Depository Receipt (ADR) came in at $1.20, compared to the year-ago figure of 90 cents, and posted revenues of $4.1 billion in the reported quarter.
In this article: MKGAF Also: PFE
Read
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Article By: Zacks Investment Research
Thursday, August 4, 2016 7:23 AM EDT
The company’s second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents, compared to the year-ago figure of 90 cents.
In this article: MKGAF
Read
All Posts

Latest Tweets for $MKGAF

No tweets yet!

PARTNER HEADLINES